Global Fund expands commitment to improve access to HIV drug

Apr 14, 2026

Communicable Diseases

Global Fund expands commitment to improve access to HIV drug

The U.S. and the Global Fund to Fight AIDS, Tuberculosis and Malaria are stepping up efforts to broaden access to Gilead's (GILD.O) HIV prevention ‌drug, with a goal of reaching 3 million people by 2028.

Initial deliveries of the drug, lenacapavir, have reached nine African countries, Global Fund said on Tuesday, adding that it would extend the provision of the treatment to 12 additional countries, including Dominican Republic, Fiji, Indonesia, Morocco, Rwanda and Thailand.

In July ⁠last year, Global Fund, which is an international partnership, and Gilead finalized their plans to supply lenacapavir to low-income countries, agreeing to provide enough doses to reach up to 2 million people over three years.

Doctors Without Borders (MSF), an independent international medical organization, said it is concerned that this does not address the fundamental barriers keeping this "game-changing" medicine out of reach for many of those who need it most.